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Abstract
Background: Burns are common injuries that are usually covered with a layer of necrotic tissue called the eschar.
Early removal of the eschar is the current standard of care, however, debridement using tangential excision is
usually traumatic and may increase wound surface. In recent years a bromelain-based debriding agent called
NexoBrid® that can remove the eschar selectively and thus causes less additional trauma was developed. Bromelain
is a pineapple-stem derived mix of proteases. In its raw form bromelain is a yellowish powder. Cases are known
where frequent inhalation of bromelain dust led to respiratory sensitization and subsequently to severe allergic
reactions. In order to activate bromelain for debridement it has to be mixed with a hydrating gel. We aimed to
assess the risk of sensitization by measuring the particle concentration in the air during the mixing process in order
to determine the safety of the product for patients as well as practitioners.
Methods: The mixing process was repeated five times in a row. Samples of the particle concentration in the
workers breathing area were taken with an air particle counting device during continuous performance. The worker
wore a lab coat and gloves but no face mask.
Results: Particle concentrations ranged from 0.010 mg/m3 to 0.012 mg/m3 (mean 0.010 mg/m3). The particles were
chemically termed as “respirable dust”.
Conclusions: We measured very low exposure levels of inhalable particles during the mixing process. Because the
particle counter could not distinguish the components of the dust, it is possible that also background particles
contributed to the results. A review of literature revealed that relatively high exposure levels are necessary for
respiratory sensitization, whereas also low exposure levels may exacerbate an allergic reaction. We suggest that
preparation of NexoBrid® is safe as long as standard safety precautions are met. Patients with known allergy to
pineapple should be treated more carefully to prevent an allergic reaction.
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Background
Bromelain as debriding agent in burns
Thermal traumas are common injuries. In the United
States alone there were half a million burns recorded in
2014; of which 200,000 patients were admitted to burn
centers [1]. Improvements in care, including early excision
and autografting, caused a significant decrease of morbidity
and mortality rates [2]. Nevertheless, excessive scarring
leading to functional restrictions and disfigurement are
issues that need to be solved in burn care currently [3].
In contrast to mechanical wounds, second and third
degree burn wounds present clinically with a layer of
necrotic tissue called eschar. This eschar makes accurate
diagnosis of burn depth challenging, which may put the
patient at risk for local and systemic complications [3, 4].
Furthermore, non-excised eschar contributes to burn
wound progression, which is associated with a conversion
from deep-partial thickness burns into full-thickness
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burns [4]. Modern burn care standards recommend early
debridement followed by autografting as standard of care.
For deep partial thickness burns, eschar removal is done
in the operation room, usually by tangential excision, until
bleeding or viable tissue is reached. However, this surgical
technique has its drawbacks: excisional debridement is
traumatic and associated with vast amounts of blood loss,
especially if hemostasis is not performed properly. In
addition, surgical wound debridement requires trained
surgical personnel and adequate tools [3]. Viable tissue is
prone to damage during tangential excision. Studies
showed that about half of the surgically excised burn
wound tissue was viable [4]. In some cases, surgical
debridement has to be delayed until accurate diagnosis of
burn depth can be performed in order to determine
whether there is a need for fascial excision.
Chemical and enzymatic approaches have been tried
to speed up this process. Initial approaches toward enzym-
atic debridement used a combination of papain, sodium
salicylate and cysteine hydrochloride. Earlier enzymatic
debriding agents were slow, and thereby useless for early
burn wound debridement [4], and even increased the risk
of infections via maceration of the eschar [3].
In recent years, the bromelain-based debriding agent
NexoBrid® has revolutionized enzymatic burn wound de-
bridement. It allows fast and early debridement of second
to third degree burn wounds. Recent studies demon-
strated that NexoBrid® removed the burn eschar signifi-
cantly faster than other enzymatic techniques. Compared
to surgical debridement, it decreased the need for further
surgical excision as well as the amount of excised tissue
significantly. Further, the authors showed that in patients
treated with NexoBrid® surgery related blood loss was sig-
nificantly lower in comparison to the standard of care
treated patients [3]. In an animal study on pigs, the use of
the enzymatic debriding agent lead to a preservation of
the zone of stasis and subsequent lack of burn wound
progression [4]. In a similar trial, the bromelain agent
NexoBrid® also lead to significantly faster reepitheliali-
sation of partial thickness burns as compared to a
bromelain-free vehicle gel [5].
What is bromelain?
Bromelain is the aqueous crude extract from the stems
of immature pineapple plants. It consists of glycopro-
teins and carbohydrates, as well as a complex mixture of
enzymes including phosphatases, glycosidases, peroxi-
dases, and cellulases [6]. Since its introduction, bromelain
has been widely used in pharmaceutical industries, food
production and in diagnostic laboratories [7]. Nowadays
bromelain is extracted from cooled pineapple juice rather
than pineapple stems. After a process involving centrifu-
gation, ultrafiltration, and lyophilisation, bromelain is
maintained as a yellowish powder. The activity of the
bromelain enzyme can be determined with different
agents such as casein (FIP units), gelatine (gelatine diges-
tion units), or chromogenic tripeptides [6, 8].
For medical purposes, various therapeutic effects of
bromelain are used: It has shown beneficial effects on
circulation and blood coagulation such as prevention
and reduction of edema as well as being a supporter of
fibrinolysis and inhibitor of platelet aggregation. It has
anti-inflammatory effects via reduction of prostaglandin
E2 and thromboxane A2. In a mouse cancer model it
even prevented metastases [6]. Furthermore, in children
with acute sinusitis bromelain led to a faster symptom
relief in comparison to the standard therapy (antiphlogis-
tics, antibiotics and physical therapy) [9]. And decades ago
pineapple juice has been used as anthelmintic agent [7].
As recent studies showed, bromelain as debriding agent in
burns is becoming more and more popular [3–6, 8].
Allergy to bromelain
Studies suggest that sensitization to proteolytic enzymes
takes place in the humans’ respiratory tract. In literature
few cases of allergic reactions caused by bromelain are
described. In all cases described, sensitization to brome-
lain occurred due to occupational exposure to inhalable
dust. The reported working environments where these
incidents occurred were located in pharmacologic and
diagnostic laboratories. All described cases had victims
that had frequently been exposed to bromelain-containing
dust [7, 10, 11]. However, not all to bromelain exposed
workers developed allergic symptoms [7].
The observed symptoms following bromelain exposure
ranged from rhinitis and ocular itching to severe asth-
matic episodes requiring immediate medical treatment
[7, 10, 11]. In some subjects, however, pineapple inges-
tion could trigger gastric distensions and nausea [11]. In
the cases where blood testing was performed, all patients
with bromelain allergy showed bromelain-specific IgE-
antibodies. In most of the concerned patients, total
IgE-levels were normal indicating an absence of atopic
disease [7]. In diagnostic testing, symptoms occurred after
exposure to inhalable particles [10], after prick-testing [7]
and even after eating a pineapple [11].
Aim of study
Because the medical literature indicates that an allergic
reaction to bromelain is mainly work related, we aimed
to estimate the risk for personnel working with the
bromelain-based debriding agent NexoBrid®. NexoBrid®
has to be prepared as follows: Before application to the
wound, bromelain powder needs to be mixed with an ac-
tivating hydrating gel [4]. This has to be done directly
before administration because bromelain deteriorates in
a liquid state through self-digestion [6]. The risk of re-
spiratory sensitization is probably related to the allergen
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concentration [12]. We aimed to assess the concentration
of inhalable particles in the air during preparation of
NexoBrid®, to investigate whether there is a potential risk
of inhalation of high concentrations of bromelain dust.
Methods
In January 2015, one worker performed routine proce-
dures including the mixing of 5 g bromelain powder with
50 g of the gel vehicle in the original product container.
The work was conducted on a normal lab bench with no
local exhaust. Measurements of inhalable particles in the
workers breathing zone were taken using the air particle
counting device TSI Side Pack AM510 (TSI Incorporated,
USA; calibrated on September 2014) (Fig. 1). The mixing
process was repeated five times in a row. Each mixing
cycle took 3–4 min, and sampling was done during con-
tinuous performance. The worker wore gloves and a lab
coat but no face mask.
Results
The particle concentration ranged from 0.010 to
0.012 mg/m3 (mean 0.010 mg/m3). The particles were
chemically termed as “respirable dust”. Table 1 lists the
test results.
Discussion
NexoBrid® provides the practitioner with the possibility
of single-stage complete debridement of the burn
wound. According to first results of research, the advan-
tages of enzymatic debridement are: earlier complete
debridement, less treatment-related blood loss and less
need for autografting [3]. However, blood loss was only
measured by the difference of hemoglobin and hematocrit
before and 24 h after therapy (surgical or enzymatic
debridement). The effect of administered fluid before
treatment was not taken into account. Also the possibility
of fluid loss due to extravasation into the tissue was
ignored. Still, NexoBrid® remains the most promising
enzymatic debriding agent available to date.
The results obtained in our measurements during mixing
of bromelain with hydrating gel indicated low exposure
levels of inhalable particles. With the particle counter used
it was not possible to distinguish the components of the
dust. Thus it is possible that background particles contrib-
uted to the results of the measurements.
In the cases of bromelain sensitization due to exposure
at work, Galleguillos and Rodriguez mentioned that
none of the patients described wore any safety protec-
tion and that dust inhalation was massive [10]. The
working environment of the cases described by Gailhofer
et al. was not elucidated more closely, but in the workers
investigated, frequent and intensive contact with brome-
lain dust has been reported [7]. While all authors describe
bromelain as a potent sensitizer, it seems that continuous
and intensive contact with the substance is the key to
sensitization. In a review of the literature Arts et al. found
evidence that relatively high allergen concentrations are
necessary to develop a respiratory allergy. Arts et al. fur-
ther suggest that prevention of high concentrations will
prevent workers from developing an allergy. In people
already sensitized, however, very low exposure levels may
exacerbate an allergic reaction [12].
We measured low particle levels in the breathing air of
a worker preparing bromelain powder, and the steps are
equivalent for the preparation of NexoBrid®. We postulate
that the risk of sensitization seems to be very low for the
agent handling personnel. In addition, the risk for the pa-
tient to inhale bromelain particles is low, because we
know that the enzymatic burn wound debridement with
NexoBrid® has to be applied during sedoanalgesia; the pa-
tient would usually be wearing an oxygen mask, which
prevents the patient from direct exposure. Thus, contact
of the patient’s respiratory mucosa with bromelain dust
and thus sensitization is highly improbable. The manufac-
turers of Nexobrid® however do not recommend the
repeated use of the agent in the same patient due to the
potential risk of sensitization via the skin.
Just as bromelain, papain is a plant-derived cystine-
proteinase [6]. Inhalation of Papain is known to cause lung
injuries in mice [13, 14]. Of bromelain no such effects
have been described so far. Animal studies should be
Fig. 1 TSI AM510 Aerosol Monitor
Table 1 Test results
Test Concentration
(mg/m3)
Chemical Properties Preparation Time (min)
1 0.010 Respirable Dust 4
2 0.011 Respirable Dust 4
3 0.010 Respirable Dust 3
4 0.012 Respirable Dust 3
5 0.010 Respirable Dust 3
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carried out to investigate the effects of bromelain inhal-
ation on the lung tissue more thoroughly.
Conclusions
Due to our findings and the results obtained from a brief
literature review, we suggest that preparation of NexoBrid®
requires no extra safety precautions. Still, appropriate
handling of the debriding agent, including wearing of
gloves and protective clothing as well as a surgical mask,
is mandatory. Additional protective gear as preparation of
the powdery agent under a hood is an option, however
not required. Nevertheless, patients with known allergy to
pineapple or bromelain should be treated more carefully
to prevent allergic reactions.
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